Last reviewed · How we verify

Visipaque - Hydrocortancyl

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule

Visipaque is a non-ionic, iso-osmolar contrast medium that enhances radiographic visualization of blood vessels and organs during diagnostic imaging procedures.

Visipaque is a non-ionic, iso-osmolar contrast medium that enhances radiographic visualization of blood vessels and organs during diagnostic imaging procedures. Used for Coronary angiography and ventriculography, Peripheral vascular angiography, Cerebral angiography.

At a glance

Generic nameVisipaque - Hydrocortancyl
SponsorAssistance Publique - Hôpitaux de Paris
Drug classNon-ionic iso-osmolar contrast medium
ModalitySmall molecule
Therapeutic areaDiagnostic Imaging
PhaseFDA-approved

Mechanism of action

Visipaque contains iopamidol, an iodinated contrast agent that increases radiodensity in targeted anatomical regions, allowing for improved visualization during angiography and other radiographic procedures. The iso-osmolar formulation is designed to minimize osmotic stress on tissues and reduce nephrotoxicity compared to hyperosmolar contrast agents.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: